Who we are

At Soteria Biotherapeutics, we are developing a next generation of bispecific T-cell engagers to treat patients with solid tumor cancers. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. Our mission is to safely harness the body’s natural immune system to defeat cancer and transform patients’ lives.

The company was founded in 2018 by Jim Wells, PhD, renowned protein engineer and professor at UC San Francisco, Zachary Hill, PhD, and Alexander Martinko, PhD. The company has exclusively licensed technology from UC San Francisco based on the work of Drs. Wells, Hill and Martinko.